Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Operating Margin (2016 - 2025)

Adma Biologics' Operating Margin history spans 13 years, with the latest figure at 45.09% for Q4 2025.

  • For Q4 2025, Operating Margin rose 1249.0% year-over-year to 45.09%; the TTM value through Dec 2025 reached 37.52%, up 493.0%, while the annual FY2025 figure was 37.53%, 493.0% up from the prior year.
  • Operating Margin reached 45.09% in Q4 2025 per ADMA's latest filing, up from 38.01% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 45.09% in Q4 2025 to a low of 94.49% in Q1 2021.
  • Average Operating Margin over 5 years is 3.56%, with a median of 3.55% recorded in 2023.
  • Peak YoY movement for Operating Margin: soared 13250bps in 2021, then tumbled -149bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 23.98% in 2021, then surged by 49bps to 12.12% in 2022, then skyrocketed by 259bps to 19.26% in 2023, then surged by 69bps to 32.6% in 2024, then surged by 38bps to 45.09% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Operating Margin are 45.09% (Q4 2025), 38.01% (Q3 2025), and 35.08% (Q2 2025).